Description:
TAY-SACHS DISEASE; TSD
HEXOSAMINIDASE A; HEXA
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Lipid Metabolism |
Cell Type
|
Fibroblast
|
Transformant
|
Untransformed
|
Race
|
White
|
Ethnicity
|
ASHKENAZI
|
Family Member
|
1
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
Passage Frozen |
9 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
MUTATION VERIFICATION |
Myerowitz (Proc Natl Acad Sci USA 85:3955 1988) observed 1 normal alpha chain allele and 1 alpha chain with a splice junction mutation consisting of a cytidine residue substituting for a guanosine as the first nucleotide at the 5 prime boundary of intron 12. The same observation was reported by Ohno & Suzuki (Biochem Biophys Res Comm 153:463 1988). Arpaia et al (NATURE 333:85-86 1988) also confirmed that this Ashkenazi Tay-Sachs disease patient is heterozygous for two different mutations the splice mutation identified by a Dde I site and another mutation as yet undefined at the molecular level. Myerowitz and Costigan (J Biol Chem 263:18587-18589 1988) observed that the other alpha chain allele from this patient had a 4 base pair insertion in exon 11. The same insertion was found in her mother. The mutation introduces a premature termination signal in exon 11 which results in a deficiency of mRNA. This lesion was found in approximately 70% of Tay-Sachs carriers in the Ashkenazi Jewish population. Myerowitz and Hogikyan (SCIENCE 232:1646-1648 1986) observed that on the basis of DNA hybridization analyses using a cDNA coding for the alpha chain of human B-hexosaminidase the alpha chain gene for this Ashkenazi Tay-Sachs patient appears intact while the alpha chain gene of French-Canadian patients has a 5 prime deletion of approximately 5 to 8 kilobases. Paw et al (Proc Natl Acad Sci USA 86:2413-2417 1989) reported that these fibroblasts from an infantile Tay-Sachs disease patient lacked the serine for glycine substitution at position 269 of the alpha-subunit of B-hexosaminidase which was observed for adult-onset and chronic GM2 gangliosidosis patients of Ashkenazi Jewish origin. |
|
URACIL DNA GLYCOSYLASE |
Seal et al (Proc Natl Acad Sci USA 85:2339-2343, 1988) reported that monoclonal antibody, 40.10.09 to normal uracil DNA glycosylase had normal immunoreactivity with the uracil DNA glycosylase from this cell culture. In contrast, the antibody did not recognize or inhibit the native enzyme from five different Bloom syndrome cultures. |
|
beta-N-acetylhexosaminidase (hexosaminidase A) |
According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.2.1.52; 0% activity. |
|
Gene |
HEXA |
Chromosomal Location |
15q23-q24 |
Allelic Variant 1 |
606869.0001; TAY-SACHS DISEASE |
Identified Mutation |
c.1274_1277dupTATC; Myerowitz and Costigan [J Biol Chem 263: 18587 (1988)] demonstrated that the most frequent DNA lesion in Tay-Sachs disease of Ashkenazi Jews is a 4-bp insertion in exon 11. This mutation introduces a premature termination signal in exon 11, resulting in a deficiency of mRNA. This is the most frequent defect underlying Tay-Sachs disease in the Ashkenazi Jewish population. This mutation is alternatively designated 1277TATC; see 272800.0054. |
|
Gene |
HEXA |
Chromosomal Location |
15q23-q24 |
Allelic Variant 2 |
606869.0002; TAY-SACHS DISEASE |
Identified Mutation |
IVS12DS, G>C, +1; Arpaia et al. [Nature 333: 85 (1988)] identified a single-base mutation in a cloned fragment of the HEXA gene from an Ashkenazi Jewish patient with Tay-Sachs disease. The change, a G-to-C substitution in the first nucleotide of intron 12, was expected to result in defective splicing of the mRNA. A test for the mutant allele based on amplification of DNA by the PCR and cleavage of a DdeI restriction site generated by the mutation showed that this case. This mutation, the second most frequent among Ashkenazi Jews, accounts for approximately 13% of cases in this ethnic group. |
Remarks |
Ashkenazi; no detectable hexosaminidase A activity by electrophoresis; no detectable alpha chain synthesis; no detectable alpha chain mRNA; 1 alpha chain allele has a splice junction mutation and the other a 4 bp insertion in exon 11 |
Triggs-Raine BL, Feigenbaum AS, Natowicz M, Skomorowski MA, Schuster SM, Clarke JT, Mahuran DJ, Kolodny EH, Gravel RA, Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. N Engl J Med323:6-12 1990 |
PubMed ID: 2355960 |
|
Paw BH, Kaback MM, Neufeld EF, Molecular basis of adult-onset and chronic GM2 gangliosidoses in patients of Ashkenazi Jewish origin: substitution of serine for glycine at position 269 of the alpha-subunit of beta-hexosaminidase [published erratum appears in Proc Natl Acad Sci U S A 1989 Jul;86(14):5625] Proc Natl Acad Sci U S A86:2413-7 1989 |
PubMed ID: 2522660 |
|
Arpaia E, Dumbrille-Ross A, Maler T, Neote K, Tropak M, Troxel C, Stirling JL, Pitts JS, Bapat B, Lamhonwah AM, et al, Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Nature333:85-6 1988 |
PubMed ID: 3362213 |
|
Myerowitz R, Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group. Proc Natl Acad Sci U S A85:3955-9 1988 |
PubMed ID: 3375249 |
|
Myerowitz R, Costigan FC, The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J Biol Chem263:18587-9 1988 |
PubMed ID: 2848800 |
|
Ohno, Molecular genetics of B-N-acetyl-hexosaminidase alpha subunit mutations (from Lipid Storage Disorders, Plenum Publishing Corp) "Lipid Storage Disorders"1988, pp215:18587-9 1988 |
PubMed ID: 2848800 |
|
Ohno K, Suzuki K, A splicing defect due to an exon-intron junctional mutation results in abnormal beta-hexosaminidase alpha chain mRNAs in Ashkenazi Jewish patients with Tay-Sachs disease. Biochem Biophys Res Commun153:463-9 1988 |
PubMed ID: 2837213 |
|
Seal G, Brech K, Karp SJ, Cool BL, Sirover MA, Immunological lesions in human uracil DNA glycosylase: association with Bloom syndrome. Proc Natl Acad Sci U S A85:2339-43 1988 |
PubMed ID: 3353381 |
|
Myerowitz R, Hogikyan ND, Different mutations in Ashkenazi Jewish and non-Jewish French Canadians with Tay-Sachs disease. Science232:1646-8 1986 |
PubMed ID: 3754980 |
|
Myerowitz R, Proia RL, cDNA clone for the alpha-chain of human beta-hexosaminidase: deficiency of alpha-chain mRNA in Ashkenazi Tay-Sachs fibroblasts. Proc Natl Acad Sci U S A81:5394-8 1984 |
PubMed ID: 6236461 |
|
Desnick, Robert J. and Kabach, Michael M. (editors), Mutations in the GM2 gangliosidoses (from Tay-Sachs Disease, Academic Press) Proc Natl Acad Sci U S App117-120:5394-8 1984 |
PubMed ID: 6236461 |
dbSNP |
dbSNP ID: 10587 |
Gene Cards |
HEXA |
Gene Ontology |
GO:0004563 beta-N-acetylhexosaminidase activity |
|
GO:0005764 lysosome |
|
GO:0005975 carbohydrate metabolism |
|
GO:0006687 glycosphingolipid metabolism |
|
GO:0016798 hydrolase activity, acting on glycosyl bonds |
NCBI Gene |
Gene ID:3073 |
NCBI GTR |
272800 TAY-SACHS DISEASE; TSD |
|
606869 HEXOSAMINIDASE A; HEXA |
OMIM |
272800 TAY-SACHS DISEASE; TSD |
|
606869 HEXOSAMINIDASE A; HEXA |
Omim Description |
B VARIANT GM2 GANGLIOSIDOSIS |
|
GM2-GANGLIOSIDOSIS, ADULT CHRONIC TYPE, INCLUDED |
|
GM2-GANGLIOSIDOSIS, TYPE I |
|
HEXA DEFICIENCYHEXOSAMINIDASE A, INCLUDED; HEXA, INCLUDED |
|
HEXOSAMINIDASE A DEFICIENCY |
|
HEXOSAMINIDASE A DEFICIENCY, ADULT TYPE, INCLUDED |
|
TAY-SACHS DISEASE, JUVENILE, INCLUDED |
|
TAY-SACHS DISEASE, PSEUDO-AB VARIANT, INCLUDED |
|
TAY-SACHS DISEASE, VARIANT B1, INCLUDED |
|
TAY-SACHS DISEASE; TSD |
Passage Frozen |
9 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Substrate |
None specified |
Subcultivation Method |
trypsin-EDTA |
Supplement |
- |
|
|